Search Results

You are looking at 251 - 260 of 466 items for :

  • Refine by Access: All x
Clear All
Full access

Jennifer M. Weiss, Samir Gupta, Carol A. Burke, Lisen Axell, Lee-May Chen, Daniel C. Chung, Katherine M. Clayback, Susan Dallas, Seth Felder, Olumide Gbolahan, Francis M. Giardiello, William Grady, Michael J. Hall, Heather Hampel, Rachel Hodan, Gregory Idos, Priyanka Kanth, Bryson Katona, Laura Lamps, Xavier Llor, Patrick M. Lynch, Arnold J. Markowitz, Sara Pirzadeh-Miller, Niloy Jewel Samadder, David Shibata, Benjamin J. Swanson, Brittany M. Szymaniak, Georgia L. Wiesner, Andrew Wolf, Matthew B. Yurgelun, Mae Zakhour, Susan D. Darlow, Mary A. Dwyer, and Mallory Campbell

surgical management of duodenal findings may have their small bowel evaluated with capsule endoscopy or CT/MRI enterography prior to surgery to identify large lesions that might modify the surgical approach. Although individuals may be considered for

Full access

Crystal Denlinger and Terry S. Langbaum

and chest CT (with or without contrast) every 6 to 12 months for 2 years, then examination and a chest CT without contrast annually. PET or brain MRI is not indicated. Prostate Cancer In prostate cancer, the intensity of checking prostate

Full access

Joseph M. Herman

started using radiation oncology benefit managers (ROBMs). 8 ROBMs are used by insurance companies to control use of high-tech imaging modalities, such as PET and MRI, and more recently to control use of expensive radiation treatments, such as IMRT, SABR

Full access

Mitul Gandhi and Adam Petrich

-cHL ( ClinicalTrials.gov identifier: NCT01771107). Given the reports of PML in patients treated with BV, eligibility criteria will include absolute CD4 count greater than 50 cell/μL, active antiretroviral therapy, and a pretreatment brain MRI. Until prospective

Full access

radiographs, CT scans, MRI, functional nuclear medicine imaging (PET, SPECT), and ultrasound. NCCN Imaging AUC are available through a Web-based user interface that provides a searchable and user-customized display of approved NCCN Imaging AUC. The complete

Full access

Ashley E. Ross

who need primary treatment, available tests currently do not aid in the decision between radical prostatectomy and radiation therapy as primary therapy. Molecular tests should be put in the context of current practice, where multiparametric MRI

Full access

John A. Thompson

less from stage IA to IB. 5 Workup A common scenario observed in NCCN melanoma clinics is the arrival of newly diagnosed asymptomatic patients with stage I and IIA disease who have undergone staging PET/CTs, MRIs, or both. Although a workup to

Full access

Eve Henry, Victor Villalobos, Lynn Million, Kristin C. Jensen, Robert West, Kristen Ganjoo, Alexandra Lebensohn, James M. Ford, and Melinda L. Telli

recommended full year of trastuzumab therapy. Twenty-seven months after completing adjuvant radiotherapy, she presented with blurry vision that rapidly progressed to right eye blindness. Brain MRI showed right globe enhancement concerning for choroidal

Full access

Frederick M. Dirbas

breast cancer considering breast conservation . Cancer Biother Radiopharm 2004 ; 19 : 673 – 705 . 14 Godinez J Gombos EC Chikarmane SA . Breast MRI in the evaluation of eligibility for accelerated partial breast irradiation . AJR Am J

Full access

Thomas Kaley and Louis B. Nabors

, hydrocephalus, and nausea/vomiting. Specific symptoms include weakness in the extremities, visual changes, hearing loss, and inattention. 1 Diagnosis is performed using CT and MRI. Management is typically conservative, with surgery, radiation, and chemotherapy